Conflicting evidence-based guidelines and medication risks have complicated the care of individuals with low bone density. The Endocrine Society just released its most recent recommendations for pharmacologic management of postmenopausal women with osteoporosis. Their goal was to address the most challenging aspects of low bone density management with clear evidence-based guidance. Join us as we review their new recommendations, compare them with other guidelines, and discuss their impact on your practice.
The speaker will review of latest recommendations for screening for osteoporosis, assessment of fracture risk, diagnosis of osteoporosis, treatment for fracture prevention, choice of pharmacologic agent, duration of treatment, and when to refer for specialist consultation.
Join this talk for an enlightening look at health system waste and failures. Dr. Nash will provide an essential road map connecting high-value care to population health. With this model, participants will be equipped to evaluate and improve the future of patient engagement.This presentation will (1) provide an update on criteria to diagnose osteoporosis and identification of persons at high risk of fracture; (2) review treatment guidelines; and (3) discuss new concepts regarding treatment, such as drug selection, duration of treatment, drug holidays, and standard treatment approach vs. goal-directed treatment.
This talk will provide an overview of the evaluation and management of patients with osteoporosis. Current screening guidelines and diagnostic criteria for osteoporosis will be reviewed. Risk factors for osteoporosis will be identified. The evaluation of patients with osteoporosis will be discussed. Data will be provided on treatment options for osteoporosis as well as the risks and benefits of treatment.